French Company Theradiag Launches an Antigen Test in France to Detect COVID-19 in Less Than 15 Minutes
21 Septembre 2020 - 5:45PM
Business Wire
Regulatory News:
Theradiag (Paris:ALTER), a French company specializing in
diagnostic tests for autoimmune and infectious diseases, today
announces the market launch of a CE-marked antigen test for
detecting COVID-19.
On September 16, 20201, an order dated September 15, 2020,
amending the order of July 10, 2020 stipulating the general
measures required to tackle the COVID-19 epidemic in regions
emerging from the health state of emergency and those where it has
been prolonged, was published in the French Official Journal.
Pursuant to this order, antigen tests are now officially approved
for detecting
COVID-19 among asymptomatic patients in France, a measure
designed to ease pressure on medical biology labs.
The antigen test: a new diagnostic tool for tackling
COVID-19
Like RT-PCR tests, antigen tests are carried out using a swab to
take a nasopharyngeal sample.
The swab is then analyzed directly at the test location, without
the need for specific equipment or personnel. Delivering a result
in less than 15 minutes after taking the sample, the test detects
the presence of SARS-CoV-2 virus proteins or virus fragments,
unlike RT-PCR tests which determine the presence of genetic
material (DNA, genomes, etc.) belonging to the virus.
The test was developed by CerTest Biotec, a longstanding Spanish
partner of Theradiag specializing in direct detection of
respiratory pathogens using rapid tests.
Theradiag: the French specialist in lab-based
diagnosis
Founded in 1986, Theradiag specializes in the development of
diagnostics capable of measuring treatment efficacy, particularly
in the field of biotherapy, for autoimmune diseases and cancer, a
discipline known as theranostics (therapy + diagnostics), in which
Theradiag is the world leader.
Going further than mere diagnostics, theranostics is designed to
enable clinicians to define individual treatment for each patient
by controlling treatment efficiency and anticipating potential
side-effects inherent in biotherapies. Theradiag seeks to promote
customized medicine by establishing individual treatment tailored
to the specific needs of each patient.
The market launch of the antigen test forms part of the campaign
Theradiag launched in April to contribute to tackling COVID-19,
involving the development of serology tests to detect specific
COVID-19 antibodies in patients. The new test expands Theradiag’s
range of tools for diagnosing COVID-19.
Theradiag CEO Bernard de Castelnau said: “The current
resurgence of COVID-19 infections has increased the need for rapid
and effective diagnostic tests. By launching this antigen test in
France, Theradiag intends to consolidate and step up its support
for patients and health authorities in tackling this pandemic.”
***
About Theradiag Theradiag is the market leader in
biotherapy monitoring. Capitalizing on its expertise in the
diagnostics market, the Company has been developing, manufacturing
and marketing innovative in vitro diagnostic (IVD) tests for over
30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people.
For more information about Theradiag, please visit our website:
www.theradiag.com
--------------------------
1 Source:
https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042331277
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200921005649/en/
Media Relations NewCap agency Nicolas
Mérigeau Tel.: +33 (0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theradiag (EU:ALTER)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024